These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 34069295)

  • 1. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis.
    Guberna L; Nyssen OP; Chaparro M; Gisbert JP
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34069295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis.
    Huguet M; Pereira B; Goutte M; Goutorbe F; Dubois A; Bommelaer G; Buisson A
    Inflamm Bowel Dis; 2018 Jan; 24(2):261-268. PubMed ID: 29361101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.
    Srinivasan A; Gilmore R; van Langenberg D; De Cruz P
    Therap Adv Gastroenterol; 2022; 15():17562848211070940. PubMed ID: 35126667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
    Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
    Casanova MJ; Chaparro M; Mínguez M; Ricart E; Taxonera C; García-López S; Guardiola J; López-San Román A; Iglesias E; Beltrán B; Sicilia B; Vera MI; Hinojosa J; Riestra S; Domènech E; Calvet X; Pérez-Calle JL; Martín-Arranz MD; Aldeguer X; Rivero M; Monfort D; Barrio J; Esteve M; Márquez L; Lorente R; García-Planella E; de Castro L; Bermejo F; Merino O; Rodríguez-Pérez A; Martínez-Montiel P; Van Domselaar M; Alcaín G; Domínguez-Cajal M; Muñoz C; Gomollón F; Fernández-Salazar L; García-Sepulcre MF; Rodríguez-Lago I; Gutiérrez A; Argüelles-Arias F; Rodriguez C; Rodríguez GE; Bujanda L; Llaó J; Varela P; Ramos L; Huguet JM; Almela P; Romero P; Navarro-Llavat M; Abad Á; Ramírez-de la Piscina P; Lucendo AJ; Sesé E; Madrigal RE; Charro M; García-Herola A; Pajares R; Khorrami S; Gisbert JP
    Inflamm Bowel Dis; 2020 Mar; 26(4):606-616. PubMed ID: 31504569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
    Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
    Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
    Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.
    Sahu P; Vuyyuru SK; Kante B; Agarwal A; Sharma R; Das P; Panwar R; Jain S; Bopanna S; Makharia G; Kedia S; Ahuja V
    Indian J Gastroenterol; 2020 Aug; 39(4):388-397. PubMed ID: 32880844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.